Company / Capital Returned to Shareholders
Edwards Lifesciences Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$893.4M
FY2025
5-year range
$512.8M / $1.7B
FY2021-FY2025
Trend
-22.9%
vs FY2024
Sector context
#21 of 108
Health Care
What the data says
Edwards Lifesciences's capital returned to shareholders of $893M is higher than 81% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders has fluctuated over the past 10 years, ranging from $263M in FY2019 to $1.7B in FY2022.
Based on SEC 10-K filings.
$893M in FY2025 with a 5-year CAGR of +7.4%. Top quartile in the Health Care sector.
Improved from $513M to $893M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -19.7%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Sector benchmark
+18.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, capital returned to shareholders decreased 22.9% year-over-year.
- Ranks #21 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $893.4M | -22.9% |
| FY2024 | $1.2B | +126.1% |
| FY2023 | $512.8M | -70.3% |
| FY2022 | $1.7B | +236.8% |
| FY2021 | $512.8M | -18.0% |
| FY2020 | $625.4M | +137.5% |
| FY2019 | $263.3M | -66.9% |
| FY2018 | $795.5M | +4.2% |
| FY2017 | $763.3M | +15.2% |
| FY2016 | $662.3M | +136.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026